The observation that CD47 × PD‐L1 BisAb treatment elicited enhanced CD8+ TIL formation and function led us to ask whether tumor protection observed upon CD47 × PD‐L1 BisAb treatment was CD8+ T cell dependent. This evidence concerns the gene CD8A and neoplasm.